CellSource Co

CellSource Co FCF/Net Income

The Free Cash Flow to Net Income Ratio of CellSource Co (4880.T) as of Oct 27, 2026 is 2,719.81 %. In the previous year, Free Cash Flow to Net Income Ratio was 41.38 % — a change of 6,472.28% (higher).

FCF/Net Income

2,719.81 %

YoY

6,472.28%

Last updated:

Free Cash Flow to Net Income Ratio of CellSource Co is 2025 2,719.81 % . Free Cash Flow to Net Income Ratio of CellSource Co was 2024 41.38 % . It decreases by 6,472.28% higher compared to the previous year.

The CellSource Co FCF/Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Net Income
Date
FCF/Net Income
Jan 1, 2018
97.77 JPY
Jan 1, 2019
72.75 JPY
Jan 1, 2020
109.51 JPY
Jan 1, 2021
129.47 JPY
Jan 1, 2022
73.97 JPY
Jan 1, 2023
54.01 JPY
Jan 1, 2024
41.38 JPY
Jan 1, 2025
2,719.81 JPY
The CellSource Co FCF/Net Income history
YEARFCF/Net IncomeYoY
2,719.81 %+6,472.28%
41.38 %-23.38%
54.01 %-26.98%
73.97 %-42.87%
129.47 %+18.22%
109.51 %+50.53%
72.75 %-25.59%
97.77 %+6.71%
91.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Free Cash Flow to Net Income Ratio of CellSource Co is 2,719.81 % in 2025.

Free Cash Flow to Net Income Ratio of CellSource Co changed from 41.38 % to 2,719.81 %, representing a 6,472.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Net Income Ratio CellSource Co since 2006 – with annual values, charts, and detailed analysis.

The FCF/Net Income ratio measures cash flow quality. Ratios consistently above 100% suggest high-quality earnings with strong cash backing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Net Income Ratio's CellSource Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow to Net Income Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow to Net Income Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — CellSource Co

All Key Metrics — CellSource Co